Emergence of piperacillin/tazobactam-resistant Escherichia coli.
Mohammedi
I
I
Tigaud
S
S
Tournadre
J P
JP
D021821:Communicable Diseases, Emerging / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology*; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology*; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology*; D005602:France / Q000453:epidemiology; D006801:Humans; D017053:Infection Control; D007362:Intensive Care Units; D018579:Patient Selection; D010397:Penicillanic Acid / Q000031:analogs & derivatives*; D010406:Penicillins; D010878:Piperacillin; D000078142:Tazobactam; D065093:beta-Lactamase Inhibitors
D010406:Penicillins; D065093:beta-Lactamase Inhibitors; D010397:Penicillanic Acid; D000078142:Tazobactam; D010878:Piperacillin